CLAIMS

What is claimed is:

1. Use of an effective amount of compound [(1S)-2,2-difluorocyclo-propyl] [(1R,5S)-3-{2-[(1-methyl-1H-pyrazol-4-yl) amino] pyrimidin-4-yl}-3,8-diazabicyclo [3.2.1] oct-8-yl] methanone (Brepocitinib)



;

or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating Dermatomyositis (DM) in a subject in need thereof, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in a dosage of 10 mg to 60 mg.

2. The use of claim 1, wherein the administration of an effective amount of the compound or pharmaceutically acceptable salt thereof to the subject has one or more effects selected from the group consisting of:
    a. decreases or inhibits IFN-I activity in the subject;
    b. decreases or inhibits cytokine signaling dysregulation implicated in DM;
    c. prevents or reduces damage in human myocytes and microvasculature; and
    d. interferes with DM life cycle.
3. The use of claim 1 or 2, wherein the pharmaceutically acceptable salt is p-toluenesulfonic acid salt.
4. The use of any one of claims 1-3, wherein the compound or pharmaceutically acceptable salt thereof is to be administered orally.

5. The use of any one of claims 1-4, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in a dosage of about 30 mg.
6. The use of any one of claims 1-4, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in a dosage of about 15mg.
7. The use of any one of claims 1-6, wherein the compound or pharmaceutically acceptable salt thereof is to be administered daily.
8. The use of any one of claims 1-6, wherein the compound or pharmaceutically acceptable salt thereof is to be administered in divided doses of two, three or four times per day.
9. The use of any one of claims 1-8, wherein the compound or pharmaceutically acceptable salt thereof is to be administered for less than 104 weeks or about 104 weeks.
10. The use of any one of claims 1-8, wherein the compound or pharmaceutically acceptable salt thereof is to be administered for more than 4 weeks or about 4 weeks.
11. The use of any one of claims 1-10, wherein the subject is a mammal.
12. The use of claim 11, wherein said mammal is a human.
13. The use of claim 11, wherein said mammal is a canine.
14. The use of any one of claims 1-13, wherein the administration of the compound or pharmaceutically acceptable salt thereof enables steroid tapering.